Peritoneal Nodules and Cytoreductive - PowerPoint Presentation

Slide1

Slide2

Peritoneal Nodules and

Cytoreductive

Surgery

By

dr.Ahmed

Samir

Surgical oncology senior registrar

MD,

Msc

,

MBBch

Slide3

Etymology

“Peritoneum” is derived from the

greek

word peritonaion

:

peri

 means "around," while  

teino

 means "to stretch"; thus, "peritoneum" means "stretched over.

Slide4

Introduction

Peritoneal

carcinomatosis

(GI and ovarian), mesothelioma

, and

sarcomatosis

are included in the group of diseases collectively referred to, as peritoneal metastases.

It is associated with short survival and poor quality of life, and may lead to bowel obstruction, accumulation of fluid in the peritoneal cavity and pain.

NICE, 2009

Slide5

CRS with HIPEC has been used with variable success to treat

pseudomyxoma

peritonei, appendiceal mucinous

neoplasias

, peritoneal

mesothelioma

, PC from gastric, colorectal, and ovarian cancer, and other primary peritoneal surface malignancies.

(Yan et al, 2009)

(Chua et al, 2010)

(

Bakrin

et al, 2012)

(Alexander et al, 2013)

Slide6

It is a loco regional disease but not a metastatic process, can be taken curative intent

(

Sugarbaker

, 1989

).

Ovarian

Gastric

Colorectal

Pancreatic

Slide7

PERITONEAL CARCINOMATOSIS FROM OVARIAN ORIGIN

Slide8

Ovarian epithelial and primary peritoneal cancers are a major cause of mortality in developed countries

Ovarian and peritoneal carcinomas tend to be a peritoneal surface disease for a considerable part of their natural history, with systemic metastatic disease usually being observed late in the natural history of the disease.

(

Jemal

et al, 2011).

Slide9

One of the most distinct features of Epithelial Ovarian Cancer is the tendency to disseminate into the peritoneal cavity and remain confined to the peritoneum and intra-abdominal viscera. This makes it an ideal target for loco-regional therapy.

HIPEC has become a useful therapeutic strategy to obtain a higher degree of

debulking

by trying to eliminate the residual microscopic component responsible for

recurrences

(

Evgenia

et al, 2015).

Slide10

Slide11

Slide12

A meta-analysis of 6,885 patients undergoing maximal

cytoreductive

surgery (CRS) has shown a distinct survival advantage for those with maximal tumour removal and minimum residual disease

(Bristow et al, 2002).

Slide13

Peritonectomy

procedures and resections that are combined to complete

cytoreduction

procedure (

Evgenia

et al, 2015).

Slide14

PERITONEAL CARCINOMATOSIS FROM GASTRIC ORIGIN

Slide15

Gastric cancer (GC) is the second leading cause of cancer death and the fourth most common cancer in the world

(

Parkin

et al, 1999) (Kelley et al, 2003).

The 40% of patients died for GC have hepatic metastases, while the 53-60% showed a disease progression and died with peritoneal

carcinosis

(PC). The two most important factors affecting prognosis in GC are the

serosal

invasion and the lymphatic spread (Yu et al, 1995).

Slide16

PC is already present in 5-20% of patients explored for potentially curative resection also in early gastric cancer

(

Kuramoto

et al, 2009).

In contrast to lymphatic and

haematogenous

dissemination, peritoneal spread should be regarded as a

locoregional

disease extension rather than systemic metastasis (Yan et al, 2007).

Slide17

Gastric cancer staging according to 8

th

edition of AJCC staging manual

(Rice et al, 2017)

Slide18

A positive effect of IPC has been found on overall , peritoneal recurrence and on distant metastasis. Morbidity rate is incremented by IPC.

Loco-regional

lymph-nodes invasion in

patients affected by advanced gastric cancer is not a contraindication to IPC

(

Coccolini

et al, 2013).

Slide19

PERITONEAL CARCINOMATOSIS FROM COLORECTAL ORIGIN

Slide20

Globally, colorectal cancer (CRC) is the third leading cause of cancer, totaling 1.6 million incident cases in 2013, and the fourth leading cause of cancer-related mortality, accounting for 771, 000 deaths

(Fitzmaurice et al, 2015).

Peritoneal

carcinomatosis (PC) is present in about 4–15% of patients with CRC at initial diagnosis and in up to 50% in recurrent disease following curative resection

(

Segelman

et al, 2012).

Slide21

Pathophysiology

of Peritoneal

Carcinomatosis

From

GI Malignancies

PC is thought to be a

locoregional

disease with two main mechanisms that result in peritoneal spread of the primary tumor: (1)

transmural

tumor invasion that results in the exfoliation of free cells, which directly spread to the peritoneum; (2) visceral perforation or surgical trauma that causes cell spillage from the bowel lumen or the dissected vasculature that harbor tumor cells in transit

(Stewart et al, 2005).

Slide22

Peritoneal spread results from a cascade of events that start by the loss of cell-cell adhesion molecules ,followed by

anoikis

resistance, which is cell resistance to apoptosis and usually occurs when a normal cell loses cell matrix contact. Thereby, tumor cells migrate and adhere to the peritoneal surface through

integrin and

cadherin

proteins. Then, using

proteolytic

enzymes such as matrix

metallopeptidase, the tumor cells digest the extracellular matrix, facilitating invasion, colonization, and finally, homing to the peritoneum

(de Cuba et al, 2012)(

Schempp

et al 2014).

Slide23

Colorectal cancer staging according to 8

th

edition of AJCC staging manual (Rice et al, 2017)

Slide24

A multidisciplinary approach.

patients with

extraperitoneal

disease or bulky retroperitoneal disease are not eligible for CRS with HIPEC.helical CT scan with IV contrast (bulky peritoneal disease).

diffusion-weighted magnetic resonance imaging (DW-MRI) (small peritoneal implants).

(Ibrahim et al, 2017)

Slide25

Only patients with disease amenable to complete

cytoreduction

(R0/1) should be considered since incomplete

cytoreduction (R2) is associated with worse survival.

Slide26

PERITONEAL CARCINOMATOSIS FROM PANCREATIC ORIGIN

Slide27

In comparison to other gastrointestinal malignancies, the surgery employed to date for pancreas cancer should be considered a failure as Long term survival following

pancreaticoduodenectomy

for adenocarcinoma is ten percent or less

(winter et al, 2006).The anatomic position of the pancreas deep in the retroperitoneal part of the upper abdomen causes “no touch cancer resection” to be impossible

(

Sugarbaker

, 2017).

Slide28

In the process of performing the

pancreaticoduodenectomy

with clear margins, cancer cells may gain access to the peritoneal space and grow out at high density at the resection site. The phenomenon has been called tumor cell entrapment.

Peritoneal metastases occur prior to the pancreatic resection in an estimated 10% of patients. However, after the

pancreatectomy

in patients who had no peritoneal metastases at the time of resection, 50% or more patients will develop local recurrence and/ or peritoneal metastases in follow-up

(

Sugarbaker

, 2017).

Slide29

Numerous trials and meta-analyses have attempted to establish a benefit for

radiochemotherapy

for pancreas cancer either before or after cancer resection. However, none of them have established this as a preferred method of treatment

(Khorana et al, 2016).

Slide30

A profound effect of HIPEC

gemcitabine

used following

pancreatectomy and prior to intestinal reconstruction on cancer cells lost into the peritoneal space during the cancer resection is suggested.Reduced local recurrence and peritoneal metastases post operatively.

HIPEC

gemcitabine

shows promise to reduce peritoneal seeding in patients having pancreas cancer resection in the absence of increased morbidity and mortality.

(

Sugarbaker

, 2017).

Slide31

Refrences

 

A.A. Khorana, P.B.

Mangu, J. Berlin, et al., Potentially curative pancreatic cancer:

american

Society of Clinical Oncology clinical practice guideline, J.

Clin

.

Oncol. 34 (2016) 2541-2556.Alexander HR, Bartlett DL,

Pingpank

JF,

Libutti

SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–86.Bakrin N, Cotte E,

Golfier F, Gilly FN, Freyer G, Helm W, et al. Cytoreductive surgery and hyperthermic

intraperitoneal

chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann

Surg

Oncol

. 2012;19:4052–8. Springer-

Verlag

.

Bristow RE,

Tomacruz

RS, Armstrong DK, Trimble EL,

Montz

FJ. Survival effect of maximal

cytoreductive

surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J

Clin

Oncol

. 2002; 20: 1248-1259.

Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal

carcinomatosis

undergoing complete

cytoreduction

and

hyperthermic

intraperitoneal

chemotherapy. Ann

Surg

Oncol

. 2010;17:1330–6. Springer-

Verlag

.

de Cuba EMV,

Kwakman

R, Van

Egmond

M, Bosch LJW,

Bonjer

HJ, Meijer GA, et al. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer.

Virchows

Arch. 2012;461:231–43. Springer-

Verlag

.

Fitzmaurice C, Dicker D, Pain A,

Hamavid

H,

Moradi-Lakeh

M,

MacIntyre

MF, et al. The global burden of cancer 2013. JAMA

Oncol

. 2015;1:505–23.

Ibrahim

Nassour

& Patricio M.

Polanco

. Current Management of Peritoneal

Carcinomatosis

From Colorectal Cancer: the Role of

Cytoreductive

Surgery and

Hyperthermic

Peritoneal

Chemoperfusion

.

Curr

Colorectal Cancer Rep (2017) 13:144–153

J.M. Winter, J.L. Cameron, K.A. Campbell, et al., 1423

pancreaticoduodenectomies

for pancreatic cancer: a single institution experience, J.

Gastrointest

. Surg. 10 (2006) 1199-1210.

Jemal

A, Bray F, Center MM,

Ferlay

J, Ward E, Forman D. Global cancer statistics. CA Cancer J

Clin

. 2011; 61: 69-90.

Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J

Clin

Epidemiol

2003;56(1):1–9.

Slide32

Kuramoto

M, Shimada S,

Ikeshima

S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann

Surg

2009;250: 242–6.

NICE. Interventional procedure overview of

cytoreduction

surgery followed by hyperthermic

intraoperative

peritoneal chemotherapy for peritoneal

carcinomatosis

. IPG331. London: National Institute for Health and Clinical Excellence, 2009.Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33–64.

Paul H. Sugarbaker. Strategies to improve local control of resected pancreas adenocarcinoma. Surgical Oncology 26 (2017) 63-70Rice TW, Kelsen DP, Blackstone EH, et al. gastric cancer. In:

Amin

MB, Edge SB, Greene FL, et al., editors. AJCC Cancer Staging Manual, 8th ed. New York: Springer, 2017:185-202.

Schempp

CM, von

Schwarzenberg

K, Schreiner L,

Kubisch

R,

Müller

R, Wagner E, et al. V-

ATPase

inhibition regulates

anoikis

resistance and metastasis of cancer cells. Mol Cancer Ther.2014;13:926–37. American Association for Cancer Research.

Segelman

J,

Granath

F,

HolmT

, Machado M,

Mahteme

H,Martling

A. Incidence, prevalence and risk factors for peritoneal

carcinomatosis

from colorectal cancer. Br J Surg. 2012;99:699–705. John Wiley & Sons, Ltd.

Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Jaime

Prat

; for the FIGO Committee on Gynecologic Oncology. International Journal of Gynecology and Obstetrics 124 (2014) 1–5

Stewart JH,

Shen

P, Levine EA.

Intraperitoneal

hyperthermic

chemotherapy for peritoneal surface malignancy: current status and future directions. Ann

Surg

Oncol

. 2005;12:765–77. Springer-

Verlag

.

Sugarbaker

PH,

Cuncliffe

WJ,

Belliveau

J, de

Bruijn

EA, Graves T, Mullins RE, et al. (1989) Rationale for integrating early postoperative

intraperitoneal

chemotherapy into the surgical treatment of gastrointestinal cancer.

Semin

Oncol

; 16:83-97

Sugarbaker

PH

. Management of peritoneal

carcinomatosis

.

Acta

Med

Austriaca

.

 1989;16(3-4):57-60.

Yan TD, Black D,

Sugarbaker

PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant

intraperitoneal

chemotherapy for

resectable

gastric cancer. Ann

Surg

Oncol

2007;14:2702–13.

Yan TD,

Deraco

M,

Baratti

D,

Kusamura

S, Elias D,

Glehen

O, et al.

Cytoreductive

surgery and

hyperthermic

intraperitoneal

chemotherapy for malignant peritoneal

mesothelioma

:

multiinstitutional

experience. J

Clin

Oncol

. 2009;27:6237–42. American Society of Clinical Oncology.

Yu CC,

Levison

DA, Dunn JA, et al. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in

resectable

gastric cancer. Br J Cancer 1995;71:1106–10.

Slide33